Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 593,166 | 500,919 | 659,825 | 494,333 | 439,718 |
| Cost of Goods | 102,817 | 85,905 | 68,672 | 65,976 | 85,858 |
| Gross Profit | 490,349 | 415,014 | 591,153 | 428,357 | 353,860 |
| Operating Expenses | 596,325 | 492,824 | 543,211 | 472,768 | 471,122 |
| Operating Income | -105,159 | -76,905 | 48,614 | -43,435 | -116,404 |
| Interest Expense | 38,971 | 34,376 | 33,258 | 35,253 | 31,338 |
| Other Income | -49,828 | 2,618 | -26,523 | 15,101 | 10,055 |
| Pre-tax Income | -193,958 | -108,663 | -11,167 | -63,587 | -137,687 |
| Income Tax | -110,195 | 2,907 | 5,722 | 2,348 | 183 |
| Net Income Continuous | -83,763 | -111,570 | -16,889 | -65,935 | -137,870 |
| Net Income | $-83,763 | $-111,570 | $-16,889 | $-65,935 | $-137,870 |
| EPS Basic Total Ops | -0.66 | -0.87 | -0.13 | -0.52 | -1.09 |
| EPS Basic Continuous Ops | -0.66 | -0.87 | -0.13 | -0.52 | -1.09 |
| EPS Diluted Total Ops | -0.66 | -0.87 | -0.13 | -0.52 | -1.06 |
| EPS Diluted Continuous Ops | -0.66 | -0.87 | -0.13 | -0.52 | -1.03 |
| EPS Diluted Before Non-Recurring Items | -0.65 | -0.87 | -0.13 | N/A | N/A |
| EBITDA(a) | $-90,991 | $-62,923 | $63,617 | $-29,918 | $-135,408 |